Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 196 AL 210

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

Guo S, Hernandez L, Wasiak R, Gaudig M.

J Med Econ. 2010;13(4):641-54. doi: 10.3111/13696998.2010.528101. Epub 2010 Oct 19.

Video-based coping skills to reduce health risk and improve psychological and physical well-being in Alzheimer's disease family caregivers

Williams VP, Bishop-Fitzpatrick L, Lane JD, Gwyther LP, Ballard EL, Vendittelli AP, Hutchins TC, Williams RB.

Psychosom Med. 2010 Nov;72(9):897-904. doi: 10.1097/PSY.0b013e3181fc2d09. Epub 2010 Oct 26.

[Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]

Agüera-Ortiz LF; Grupo de Investigadores del Estudio MEMORY.

Rev Neurol. 2010 Nov 1;51(9):525-34.

Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

Kayed R.

Hum Vaccin. 2010 Nov;6(11):931-5. doi: 10.4161/hv.6.11.12689. Epub 2010 Nov 1.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

Potential therapeutic agents against Alzheimer's disease from natural sources

Park SY.

Arch Pharm Res. 2010 Oct;33(10):1589-609. doi: 10.1007/s12272-010-1010-y. Epub 2010 Oct 30.

A meta-analysis of mood stabilizers for Alzheimer's disease

Xiao H, Su Y, Cao X, Sun S, Liang Z.

J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):652-8. doi: 10.1007/s11596-010-0559-5. Epub 2010 Nov 10.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80.

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial

Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR.

J Clin Psychopharmacol. 2010 Dec;30(6):683-7. doi: 10.1097/jcp.0b013e3181fa05bb.

Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease

Lannfelt L, Pettersson FE, Nilsson LN.

Nutr Rev. 2010 Dec;68 Suppl 2:S128-34. doi: 10.1111/j.1753-4887.2010.00347.x.

Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment

Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K.

Molecules. 2010 Dec 2;15(12):8804-12. doi: 10.3390/molecules15128804.

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J.

Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808.

Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond

Ganjei JK.

Drug News Perspect. 2010 Nov;23(9):573-84. doi: 10.1358/dnp.2010.23.9.1507297.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias